Dana-Farber Cancer Institute Inc. v. Director General of the National Institute of Industrial Property Intellectual Property Code, Arts. L4111-4, R411-19; Regulation (EC) No. 469/2009, Art. 3(a)
Springer Nature ·
2026-04-01
· DOI 10.1007/s40319-026-01721-w
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Dana-Farber Cancer Institute Inc. v. Director General of the National Institute of Industrial Property Intellectual Property Code, Arts. L4111-4, R411-19; Regulation (EC) No. 469/2009, Art. 3(a). “Antibody SPC”. // IIC - International Review of Intellectual Property and Competition Law. – 2026. – DOI: 10.1007/s40319-026-01721-w. – URL: https://doi.org/10.1007/s40319-026-01721-w
Dana-Farber Cancer Institute Inc. v. Director General of the National Institute of Industrial Property Intellectual Property Code, Arts. L4111-4, R411-19; Regulation (EC) No. 469/2009, & Art. 3(a) (2026). “Antibody SPC”. IIC - International Review of Intellectual Property and Competition Law. https://doi.org/10.1007/s40319-026-01721-w
Dana-Farber Cancer Institute Inc. v. Director General of the National Institute of Industrial Property Intellectual Property Code, et al. ““Antibody SPC”.” IIC - International Review of Intellectual Property and Competition Law, 2026. doi:10.1007/s40319-026-01721-w.
@article{Code2026,
title = {“Antibody SPC”},
author = {Code, Dana-Farber Cancer Institute Inc. v. Director General of the National Institute of Industrial Property Intellectual Property and L4111-4, Arts. and 469/2009, R411-19; Regulation (EC) No. and 3(a), Art.},
journal = {IIC - International Review of Intellectual Property and Competition Law},
year = {2026},
doi = {10.1007/s40319-026-01721-w},
url = {https://doi.org/10.1007/s40319-026-01721-w}
}